Movithiol (Betamethasone Valerate)

Betamethasone valerate binds to glucocorticoid receptors inside skin cells, altering gene transcription. This suppresses the release of inflammatory mediators, reduces leukocyte migration, and stabilises cell membranes, leading to decreased inflammation and immune response at the site of application.

The dosage of Movithiol is determined by the prescribing healthcare professional based on the severity of the skin condition, the area to be treated and patient‑specific factors. Patients should follow the exact instructions provided on the prescription label.

Safety data for betamethasone valerate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified clinician.

To request Movithiol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Movithiol (betamethasone valerate) is a mid‑ to high‑potency corticosteroid, offering stronger anti‑inflammatory effects than low‑potency agents such as hydrocortisone but generally less potency than ultra‑high agents like clobetasol propionate. Choice depends on disease severity, treatment area and safety considerations.

Store Movithiol at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and ensure it is out of reach of children.

Apply a thin layer of Movithiol to the affected skin area once or twice daily, as directed by the prescriber. Gently rub the medication into clean, dry skin and wash hands after application unless the hands are being treated.

Serious risks include skin atrophy, hypopigmentation, allergic contact dermatitis, and systemic effects such as adrenal suppression or Cushing‑like symptoms, especially with prolonged use over large body areas or under occlusion.

Movithiol is contraindicated in patients with known hypersensitivity to betamethasone valerate or any formulation component, in untreated bacterial, viral or fungal skin infections, and in individuals where systemic corticosteroid therapy is contraindicated without medical supervision.